ATLANTA--(BUSINESS WIRE)--Holzer Holzer & Fistel, LLC is investigating whether Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ: IPXL) and/or certain of its officers and directors complied with state and federal laws in connection with the Company’s recently disclosed problems with its Hayward, California manufacturing facility. Specifically, on March 4, 2013 Impax announced that the Food & Drug Administration issued a new Form 483 that identified twelve observations, including three repeat observations, that could negatively impact the Company’s new and pending applications with the FDA. The Company’s stock price fell dramatically on the news.
If you purchased Impax common stock before the Company’s disclosure on March 4, 2013 and have questions concerning your legal rights, you are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel Jr., Esq. or Marshall P. Dees, Esq. via email at email@example.com, or firstname.lastname@example.org, or via toll-free telephone at (888) 508-6832.
Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.